Results 281 to 290 of about 250,661 (348)

PANoptosis-related gene clusters and prognostic risk model in clear cell renal cell carcinoma. [PDF]

Front Genet
Zhao Q, Xie H, Li C, Xiong Y, Fan Y, Huang Y, Zhan Y, Zeng S.   +7 more
europepmc   +1 more source

A targeted antiferromagnetic nanoprobe for ultra‐sensitive magnetic resonance imaging detection of sub‐millimeter esophageal tumors

BMEMat, EarlyView.
We developed a cyclo‐RGD peptide‐conjugated antiferromagnetic nanoparticle (RANP) as a targeted T1 contrast agent. Under 9 T MRI conditions, RANP exhibited an r1 value of 1.88 mM−1 s−1 and a low r2/r1 ratio of 1.84, enabling the detection of esophageal tumors as small as 0.8 mm in vivo. Abstract Early, non‐invasive detection of esophageal cancer at sub‐
Wenkui Mo, Zeyu Liang, Bo Zhang, Lin Xiao, Xun Liu, Zhigao Yi, Shangzhi Xie, Qiyue Wang, Liang Shi, Taobo Luo, Feng Li, Leilei Wu, Yuanzhe Piao, Fangyuan Li, Jian Zeng, Daishun Ling   +15 more
wiley   +1 more source

Migrasome-related lncRNAs predict prognosis and immune response of clear cell renal cell carcinoma

Rong Chen, Lei Dong, Tianci Wei, Qiang Wang   +3 more
openalex   +1 more source

SPOCD1 expression in clear cell renal cell carcinoma: its implications for the prognosis and immunotherapy. [PDF]

World J Surg Oncol
Xu W, Yan L, Liu Y, Liu D, Wu D, Luo Y, Li C, Li Q, Wang T.   +8 more
europepmc   +1 more source

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

BMEMat, EarlyView.
This article introduces a biomimetic Mn‐doped polydopamine nanoplatform (HAMM NPs) coated with cancer cell membranes. It enables targeted hepatocellular carcinoma theranostics via T1/T2 dual‐mode magnetic resonance imaging and tumor microenvironment‐triggered sonodynamic therapy/chemodynamic therapy, achieving potent antitumor efficacy in subcutaneous ...
Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng   +7 more
wiley   +1 more source

Genomic and Molecular Associations with Preoperative Immune Checkpoint Inhibition in Patients with Stage III Clear Cell Renal Cell Carcinoma. [PDF]

Cancers (Basel)
Chou WH, Lawrence L, Neham E, Akilesh S, Moran AE, Corless CL, Langmesser L, Cengiz B, Eckenstein K, Liu JJ, Isharwal S, Amling CL, Strother MC, Chakiryan NH, Thomas GV.   +14 more
europepmc   +1 more source

Lipid Profile Differences in HIV‐Infected Populations With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA study flow diagram. ABSTRACT Introduction Advances in HIV management have transformed HIV into a chronic condition, resulting in improved prognosis and increased survival among people living with HIV (PLWH). Traditional risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD)—including dyslipidemia—are prevalent in PLWH.
Yovita Hartantri, Sherly Lawrensia, Steven Yulius Usman, Nenny Agustanti, Rudi Wisaksana, Nanny Natalia Mulyani Soetedjo, Bachti Alisjahbana   +6 more
wiley   +1 more source

POSTN⁺ cancer-associated fibroblast-CCL3⁺ macrophage crosstalk defines the immune-excluded tumor microenvironment in clear cell renal cell carcinoma. [PDF]

Transl Oncol
Wang Y, Yue B, Ni H, Chen J, Shi R, Wang Z, Dai X, Sheng M.   +7 more
europepmc   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source